search
Back to results

Proteomic Analysis of Human Hepatocellular Carcinoma

Primary Purpose

Carcinoma, Hepatocellular

Status
Completed
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Operation
Sponsored by
Far Eastern Memorial Hospital
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional basic science trial for Carcinoma, Hepatocellular focused on measuring Carcinoma, hepatocellular, Portal vein, Proteomics

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Arm A: Hepatocellular carcinoma with vessel invasion:

  • hepatocellular carcionoma, pathologic diagnosed.
  • image documented vessel invasion, including portal vein thrombosis
  • eligible for surgical intervension.

Arm B: hepatocellular carcinoma without vessel invasion:

  • hepatocellular carcinoma, pathologic diagnosed or clinical diagnosed according to EASL criteria.
  • no vessel invasion on image.

Arm C: Healthy hepatitis carrier:

  • patients age >18 years old with hepatitis B or C
  • normal liver function.

Sites / Locations

  • Far Eastern Memorial Hospital

Outcomes

Primary Outcome Measures

Recurrence
Evidence of clinically definite vascular invasion of hepatocellular carcinoma. Confirmed by operation. Compare the proteomic expression of tumor, non-tumor ans tumor tissue in vascular part.

Secondary Outcome Measures

Full Information

First Posted
June 2, 2009
Last Updated
February 4, 2016
Sponsor
Far Eastern Memorial Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01177631
Brief Title
Proteomic Analysis of Human Hepatocellular Carcinoma
Official Title
Proteomic Analysis of Human Hepatocellular Carcinoma Associated With Portal Vein Thrombosis
Study Type
Interventional

2. Study Status

Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
February 2009 (undefined)
Primary Completion Date
January 2010 (Actual)
Study Completion Date
January 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Far Eastern Memorial Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a pilot study to evaluate the difference between the protein expression between hepatocellular carcinoma and tumor with vessel invasion in Asian patients with hepatocellular carcinoma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carcinoma, Hepatocellular
Keywords
Carcinoma, hepatocellular, Portal vein, Proteomics

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
5 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
Operation
Intervention Description
Operation for clinically evaluated resectable hepatocelluar carcinoma. Compare the different expression of protein between tumor, non-tumor and tumor with vascular invasion part.
Primary Outcome Measure Information:
Title
Recurrence
Description
Evidence of clinically definite vascular invasion of hepatocellular carcinoma. Confirmed by operation. Compare the proteomic expression of tumor, non-tumor ans tumor tissue in vascular part.
Time Frame
one year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Arm A: Hepatocellular carcinoma with vessel invasion: hepatocellular carcionoma, pathologic diagnosed. image documented vessel invasion, including portal vein thrombosis eligible for surgical intervension. Arm B: hepatocellular carcinoma without vessel invasion: hepatocellular carcinoma, pathologic diagnosed or clinical diagnosed according to EASL criteria. no vessel invasion on image. Arm C: Healthy hepatitis carrier: patients age >18 years old with hepatitis B or C normal liver function.
Facility Information:
Facility Name
Far Eastern Memorial Hospital
City
Taipei
ZIP/Postal Code
220
Country
Taiwan

12. IPD Sharing Statement

Learn more about this trial

Proteomic Analysis of Human Hepatocellular Carcinoma

We'll reach out to this number within 24 hrs